Publicacións en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (94)

2022

  1. A Comprehensive Metabolomics Analysis of Fecal Samples from Advanced Adenoma and Colorectal Cancer Patients

    Metabolites, Vol. 12, Núm. 6

  2. Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 697-705

  3. Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs

    Cancers, Vol. 14, Núm. 19

  4. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  5. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  6. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  7. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 3, pp. 611-621.e9

  8. Risk of Colorectal Cancer and Advanced Polyps One Year after Excision of High-Risk Adenomas

    Diseases of the Colon and Rectum, Vol. 65, Núm. 9, pp. 1112-1120

  9. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

  10. Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study

    Annals of medicine, Vol. 54, Núm. 1, pp. 379-392